 "Indian pharma’s long road to redemption")
In 28 years in India’s pharmaceuticals sector, Rajiv Desai has never been busier. Most of the last six months on his calendar is marked green, indicating visits to the 12 plants of Lupin, India’s No.2 drugmaker, where Desai is a senior quality control executive. Only one day is red — a day off.
That’s what is needed these days to satisfy the US Food and Drug Administration’s (FDA) standards. “In this sector, you’re only as good as your last inspection,” Desai says.
Often dubbed “the pharmacy of the world”, India is home to the most FDA-approved plants outside of the
